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UnBACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) following second-generation drug-eluting
stent (DES) implantation is still debated.
OBJECTIVES The aim of this study was to test the noninferiority of 6 versus 12 months of DAPT in patients undergoing
percutaneous coronary intervention with second-generation DES.
METHODS The SECURITY (Second Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month
Dual Antiplatelet Therapy) trial was a 1:1 randomized, multicenter, international, investigator-driven, noninferiority study
conducted from July 2009 to June 2014. Patients with a stable or unstable angina diagnosis or documented silent
ischemia undergoing revascularization with at least 1 second-generation DES were eligible. The primary endpoint was a
composite of cardiac death, myocardial infarction (MI), stroke, deﬁnite or probable stent thrombosis, or Bleeding Aca-
demic Research Consortium (BARC) type 3 or 5 bleeding at 12 months. The main secondary endpoint was a composite of
cardiac death, MI, stroke, deﬁnite or probable stent thrombosis, or BARC type 2, 3, or 5 bleeding at 12 and 24 months.
RESULTS Overall, 1,399 patients were enrolled in the study and randomized to receive 6 months (n ¼ 682) versus
12 months (n ¼ 717) DAPT. The primary composite endpoint occurred, respectively, in 4.5% versus 3.7% (risk difference
0.8%; 95% conﬁdence interval [CI]: 2.4% to 1.7%; p ¼ 0.469) at 12 months. The upper 95% CI limit was lower than the
pre-set margin of 2%, conﬁrming the noninferiority hypothesis (p < 0.05). Moreover, no differences were observed in the
occurrence of the secondary endpoint at 12 months (5.3% vs. 4.0%, difference: 1.2%; 95% CI:1.0 to 3.4; p¼ 0.273) and
between 12 and 24months (1.5%vs. 2.2%, difference:0.7%; 95%CI:2.1 to 0.6; p¼0.289). Finally, no differenceswere
observed in deﬁnite or probable stent thrombosis at 12 months (0.3% vs. 0.4%; difference: 0.1%; 95% CI: 0.7 to 0.4;
p¼ 0.694) and between 12 and 24 months of follow-up (0.1% vs. 0%; difference: 0.1%; 95% CI:0.1 to 0.4; p¼ 0.305).
CONCLUSIONS In a low-risk population, the noninferiority hypothesis of 6 vs. 12 months DAPT following second-
generation DES implantation appears accepted for the incidence of cardiac death, MI, stroke, deﬁnite/probable
stent thrombosis, and BARC type 3 or 5 bleeding at 12 months. (Second Generation Drug-Eluting Stent Implantation
Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy; NCT00944333) (J Am Coll Cardiol 2014;64:2086–97)
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AB BR E V I A T I O N S
AND ACRONYM S
BARC = Bleeding Academic
Research Consortium
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
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2087C urrent American College of Cardiology/American Heart Association and EuropeanSociety of Cardiology guidelines recommend
administration of dual antiplatelet therapy (DAPT)
following percutaneous coronary intervention (PCI)
with drug-eluting stent (DES) implantation for a
period of at least 12 months or for 6 to 12 months in
patients not at high risk, respectively (1,2).SEE PAGE 2098 HR = hazard ratio
MI = myocardial infarction
PCI = percutaneous coronary
intervention
RCT = randomized clinical trial
ST = stent thrombosisHowever, randomized clinical trial (RCT) data
supporting these recommendations are limited. RCTs
comparing different durations of DAPT following DES
implantation have not thus far demonstrated any
beneﬁt for prolonged DAPT (3,4). Park et al. (5) found
no difference between extended DAPT (>12 months)
versus aspirin monotherapy in reducing ischemic
events or cardiac mortality after PCI with DES. The
EXCELLENT (Efﬁcacy of Xience/Promus Versus
Cypher to Reduce Late Loss After Stenting) trial
demonstrated similar target vessel failure rates with
6-month versus 12-month DAPT following DES im-
plantation (6). However, both studies were under-
powered to draw any ﬁnal conclusion regarding the
safety of clopidogrel discontinuation after 12 months.
The PRODIGY (PROlonging Dual antiplatelet treat-
ment after Grading stent-induced Intimal hyperplasia
studY) trial demonstrated the noninferiority of 6
months versus 24 months of DAPT following the im-
plantation of DES or bare-metal stents. Moreover,
prolonged DAPT was associated with a higher inci-
dence of bleeding events (3). Finally, the OPTIMIZE
(Optimized Duration of Clopidogrel Therapy Fol-
lowing Treatment With the Zotarolimus-Eluting
Stent in Real-World Clinical Practice) trial, com-
paring 3 versus 12 months of DAPT following
zotarolimus-eluting stent implantation in patients
with stable coronary artery disease, reported that 3
months of DAPT was noninferior to 12 months in terms
of the occurrence of major adverse cardiac events (7).
In the absence of appropriately powered RCTs eval-
uating new-generation DES in all-comer patients, the
optimal duration of DAPT following new-generation
DES is still debatable. Therefore, the aim of the
SECURITY (Second Generation Drug-Eluting StentBrescia, Italy; and the ##Policlinico Umberto I, Invasive Cardiology Departm
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Month Dual Antiplatelet Therapy) trial was
to explore the clinical impact of 6-month
versus 12-month DAPT in patients undergoing
PCI using second-generation DES.
METHODS
STUDY DESIGN AND POPULATION. The
SECURITY trial (NCT00944333) (8) was a
prospective, randomized, noninferiority,
investigator-driven, multicenter, interna-
tional study. The study started in July 2009
(ﬁrst patient enrolled). Because of logistic
and economic constraints, in addition to ev-
idence of slow enrollment and minimal differences in
the rate of the primary endpoint between the 2 groups
following an interim analysis, in December 2013, the
study’s steering committee, in agreement with the
members of the data safety and monitoring board,
decided to terminate patient inclusion and deﬁned a
common end date of June 15, 2014.
Inclusion criteria were symptoms of stable angina,
as deﬁned by Canadian Cardiovascular Society Clas-
siﬁcation, or unstable angina, as deﬁned by Braun-
wald classiﬁcation, or patients with documented
silent ischemia, treated with at least 1 second-
generation DES implanted in the target lesion in the
past 24 h. Additional inclusion criteria were the
presence of 1 or more de novo stenoses $70% in a
native coronary artery, patient age over 18 years, no
other DES implanted before the target procedure, and
no bare-metal stent implanted in the 3 months before
the target procedure. Exclusion criteria were patients
treated for saphenous vein graft, in-stent restenosis,
unprotected left main coronary artery, ST-segment
elevation myocardial infarction (MI) in the 48 h
before the procedure, or non–ST-segment elevation
MI in the previous 6 months; left ventricular ejection
fraction #30%; known hypersensitivity to aspirin,
thienopyridines, heparin, limus analogs, cobalt,
chromium, nickel, molybdenum, or contrast media;
history of signiﬁcant thrombocytopenia with aspirin
or thienopyridines; chronic kidney disease (creati-
nine >2 mg/dl); women during pregnancy or duringent, Rome, Italy. Fondazione Evidence, a nonproﬁt
us grants from Biosensors, Medtronic, and Terumo.
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2088lactation; active bleeding or signiﬁcant risk of
bleeding; uncontrolled hypertension; life expectancy
<24 months; and any medical condition that could
preclude follow-up, as deﬁned in the protocol. There
was no limit to the number of lesions that could be
treated.
TREATMENT PROTOCOL AND CLINICAL FOLLOW-UP.
The trial protocol and informed consent forms were
reviewed and approved by the ethical committee at
each clinical site before initiating the investigation.
All patients provided written informed consent. The
study was conducted according to the principles of
the Declaration of Helsinki, International Organiza-
tion for Standardization Guidelines, and Good Clin-
ical Practice Guidelines.
All patients in whom a target lesion met the eligi-
bility criteria, who had at least 1 second-generation
DES implanted, and who signed the informed consentAssessed for eligi
Randomized
Alloca
Follow
6-Month DATP
12-Month DATP
ITT Ana
Allocated to 6-M (n=682)
Received allocated intervention (n=680)
Did not receive allocated (n=2):
Death: 2
Lost to 24 months follow-up (n=129)
Early termination: 37
Lost to FU: 92
Discontinued intervention (n=5)
Adverse Events: 3
Other Reason: 2
Analyzed (n=682)
Excluded from analysis (n=0)
•
•
•
•
•
FIGURE 1 CONSORT Flow Diagram Showing the Study Design of the
6-M ¼ 6 month; 12-M ¼ 12 month; CONSORT ¼ Consolidated Standards o
ITT ¼ intention-to-treat; SECURITY ¼ Second Generation Drug-Eluting S
Antiplatelet Therapy.were randomized to receive 6 versus 12 months
DAPT. Randomization was performed by electronic
case report, according to a 1:1 scheme, balanced within
the center by blocks of 4. Second-generation DES used
were the Endeavor Resolute (Medtronic, Minneapolis,
Minnesota), Xience (Abbott Vascular, Abbott Park,
Illinois), Promus (Boston Scientiﬁc, Natick, Massa-
chusetts), Nobori (Terumo Corporation, Tokyo,
Japan), and Biomatrix (Biosensors Europe, Morges,
Switzerland).
Clopidogrel 75 mg per day for at least 3 days before
the procedure or a pre-procedural loading dose of a
minimum of 300 mg of clopidogrel was administered
to patients not on chronic clopidogrel therapy. In
the post-procedure period, 75 mg of clopidogrel for
6 or 12 months, according to randomization alloca-
tion, were administered. Conversely, post-procedure
use of aspirin was prescribed indeﬁnitely. Followingbility (n=1404)
 (n=1399)
tion
-Up
lysis
Other Reason: 12
Lost to 24 months follow-up (n=134)
Early termination: 38
Lost to FU: 96
Discontinued intervention (n=23)
Adverse Events: 11
Allocated to 12-M (n=717)
Received allocated intervention (n=717)
Did not receive allocated (n=0)
Excluded (n=5)
Not meeting inclusion criteria (n=4)
Declined to participate (n=0)
Other reasons (n=1)
Analyzed (n=717)
Excluded from analysis (n=0)
•
•
•
•
•
•
•
SECURITY Trial
f Reporting Trials; DAPT ¼ dual antiplatelet therapy; FU ¼ follow-up;
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2089their introduction to the market, the protocol was
amended to allow the new antiplatelet compounds
prasugrel and ticagrelor.
Follow-up assessments were done at 30  5 days, at
180  14 days (6 months), at 365 days (14 days/þ30
days), and at 730 days (14 days/þ30 days), by means
of telephone call or outpatient clinical evaluation. No
angiographic follow-up was mandatory in the proto-
col. The enrollment phase of the study was prema-
turely terminated for slow enrollment on December
10, 2013. All patients still in the study had a ﬁnal visit/
contact at a common end date (June 15, 2014). For this
reason, the duration of follow-up depended on the
study entry date. All investigators were strongly
advised to rigorously follow each enrolled patient.
An independent clinical research organization
(MediolanumCardio Research,Milan, Italy) performed
data monitoring. Data collection was done using elec-
tronic case report forms, which were reviewed for ac-
curacy and compared with source documents duringTABLE 1 Baseline Clinical Characteristics of Patients Receiving
6 Months and 12 Months of DAPT
6-Month DAPT
(n ¼ 682)
12-Month DAPT
(n ¼ 717)
Age, yrs 64.9  10.2 65.5  10.1
Female 153 (22.4) 166 (23.2)
Diabetes mellitus
Oral therapy NIDDM 162 (23.9) 179 (25.2)
Insulin therapy IDDM 44 (6.5) 44 (6.2)
Hypertension 508 (74.5) 510 (71.1)
Dyslipidemia 446 (65.4) 436 (60.8)
Smoker status
Never smoked 274 (40.5) 261 (37)
Previous smoker 239 (35.3) 238 (33.7)
Active smoker 139 (20.5) 172 (24.4)
Previous MI
NSTEMI >48 h 65 (9.5) 71 (9.9)
STEMI >48 h 80 (11.7) 73 (10.2)
Previous PCI 132 (19.4) 116 (16.2)
Previous CABG 38 (5.6) 39 (5.4)
LVEF, % 56.3  8.7 56.6  8.2
Clinical presentation
Stable angina 341 (61.6) 368 (61.6)
Unstable angina 213 (38.4) 229 (38.4)
Baseline medications
Aspirin 616 (90.3) 621 (86.6)
Clopidogrel 301 (44.1) 305 (42.5)
Statin 489 (71.7) 494 (68.9)
Heparin 377 (55.3) 401 (55.9)
Glycoprotein IIb/IIIa inhibitors 25 (3.7) 30 (4.2)
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass graft; DAPT ¼ dual antiplatelet therapy;
IDDM ¼ insulin-dependent diabetes mellitus; LVEF ¼ left ventricular ejection frac-
tion;MI¼myocardial infarction;NIDDM¼non–insulin-dependentdiabetesmellitus;
NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.onsite monitoring visits by Mediolanum Cardio
Research. All centers were monitored, and source data
veriﬁcation was performed in 40% of patients. All
events were evaluated and assigned by an indepen-
dent clinical event committee composed of interven-
tional cardiologists not participating in the study. For a
list of the other principal site investigators, please
refer to the Online Appendix of this article.
STUDY ENDPOINTS. The SECURITY trial’s primary
endpoint was a composite of cardiac death, MI,
stroke, deﬁnite or probable stent thrombosis (ST), or
Bleeding Academic Research Consortium (BARC)
criteria type 3 or 5 bleeding at 12 months.
Cardiac death included any death without a
noncardiac cause. Spontaneous MI was deﬁned by the
following criteria: cardiac enzyme elevation (troponin
T/I or creatine kinase-myocardial band) above the
upper normal limit associated with at least 1 ischemic
symptom; development of Q waves on the electro-
cardiogram; electrocardiogram changes indicative of
ischemia or coronary artery intervention.
Stroke was deﬁned as any new neurological deﬁcit
lasting >24 h associated with neuroimaging evi-
dence (computed tomography or magnetic resonance
imaging).TABLE 2 Baseline Lesion Characteristics of Patients Receiving
6 Months and 12 Months of DAPT
6-Month DAPT
(n ¼ 682)
12-Month DAPT
(n ¼ 717)
Number of lesions
1-vessel disease 383 (56.2) 424 (59.1)
2-vessel disease 221 (32.4) 210 (29.3)
3-vessel disease 77 (11.3) 82 (11.4)
4-vessel disease 1 (0.1) 1 (0.1)
Main branch lesion distribution
Left anterior descending artery 402 (43) 423 (44)
Left circumﬂex artery 133 (14.3) 137 (14.2)
Diagonal artery 38 (4) 32 (3.3)
OM and RI arteries 106 (11.2) 118 (12.3)
Right coronary artery 206 (22) 207 (21.6)
Bifurcation 95 (13.9) 103 (14.4)
Baseline TIMI ﬂow grade <3 140 (15.3) 145 (15.5)
AHA/ACC classiﬁcation
Class B 603 (64.5) 617 (64.3)
Class C 197 (21.1) 201 (21)
Baseline visual estimate
Lesion length, mm 17.6  9.8 18.1  10.8
Reference vessel diameter, mm 2.9  0.4 2.9  0.4
Minimal lumen diameter, mm 0.6  0.5 0.6  0.6
Diameter stenosis 84  10.1 84.4  9.7
Values are n (%) or mean  SD.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association;
DAPT ¼ dual antiplatelet therapy; OM ¼ obtuse marginal; RI ¼ ramus intermedius;
TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 3
6 Months
Femoral a
Radial acc
Total num
Total num
Treated le
1 lesion
>1 lesio
Average o
Total num
Stents imp
Per pati
Per lesio
Balloon pr
Stent dep
(ma
Balloon po
IVUS-guid
Mean sten
Mean sten
Total impl
Endeavo
Nobori
Biomatr
Promus
Xience s
Total impl
Single ste
Stents in o
Final % st
Serious ad
duri
Therapy a
Aspirin
Clopido
Prasugr
Ticagrel
Values are n
TIMI ﬂow g
medical occ
prolongatio
IVUS ¼ in
Colombo et al. J A C C V O L . 6 4 , N O . 2 0 , 2 0 1 4
DAPT Duration in 2nd-Generation DES Implantation N O V E M B E R 1 8 / 2 5 , 2 0 1 4 : 2 0 8 6 – 9 7
2090Bleeding events and ST were classiﬁed according to
BARC and Academic Research Consortium deﬁni-
tions, respectively (9,10).
Secondary endpoints were: 1) a composite of cardiac
death, spontaneous MI, stroke, deﬁnite or probable
ST, or BARC type 2, 3, or 5 bleeding at 12 and
24 months; 2) the cumulative incidence of the indi-
vidual components of the primary endpoint at 12 and
24 months; 3) MI; 4) urgent target vessel revasculari-
zation (coronary artery bypass surgery or PCI because
of acute cardiac ischemia); 5) bleeding events; and 6)
all-causemortality at 30 days and 6, 12, and 24months.Procedural and In-Hospital Outcomes of Patients Receiving
and 12 Months of DAPT
6-Month DAPT
(n ¼ 682)
12-Month DAPT
(n ¼ 717)
ccess 209 (30.6) 204 (28.5)
ess 465 (68.2) 502 (70)
ber of treated vessels 825 844
ber of treated lesions 934 960
sions
484 (71) 519 (72.4)
n 198 (29) 198 (27.6)
f treated lesions per patient 1.37  0.65 1.34  0.60
ber of implanted stents 1117 1150
lanted
ent 1.64  0.93 1.60  0.91
n 1.19  0.52 1.20  0.50
e-dilation (main branch) 512 (55.1) 537 (56.8)
loyment pressure
in branch), atm
14.6  2.8 14.7  3.0
st-dilation (main branch) 484 (52) 499 (52.7)
ed stent implantation 35 (3.7) 33 (3.4)
t length (main branch), mm 19.1  7.2 19.0  7.2
t size (main branch), mm 3.0  1.7 2.9  1.0
anted drug-eluting stent type
r Resolute stent 470 (42.1) 464 (40.3)
stent 283 (25.3) 314 (27.3)
ix stent 80 (7.2) 86 (7.5)
stent 126 (11.3) 124 (10.8)
tent 98 (8.8) 109 (9.5)
anted bare-metal stent 16 (1.4) 11 (1)
nt success* 999 (93.5) 1,055 (95.6)
verlap 93 (9.9) 110 (11.5)
enosis ¼ 0 834 (89.1) 852 (88.8)
verse events
ng hospitalization†
11 (1.6) 9 (1.3)
t discharge
675 (99) 713 (99.4)
grel 669 (98.1) 712 (99.3)
el 2 (0.3) 1 (0.1)
or 4 (0.6) 2 (0.3)
(%) or mean  SD. *Single stent success is deﬁned as residual stenosis <30% and
rade 3 by visual assessment. †Serious adverse events are deﬁned as any untoward
urrences that result in death, are life-threatening, require inpatient hospitalization or
n of existing hospitalization, or result in persistent or signiﬁcant disability.
travascular ultrasounds; other abbreviations as in Table 2.STATISTICAL ANALYSIS. The SECURITY trial was
designed in 2009 and powered to test the non-
inferiority of the primary endpoint of 6 versus 12
months DAPT following second-generation DES im-
plantation. The primary analysis was on the basis of
the intention-to-treat population. In addition, a per-
protocol population for primary analyses was
considered by restricting the full analysis set to pa-
tients fulﬁlling all major inclusion criteria, treated
according to the assigned group and completing
the ﬁnal assessment. If the sample size of the
per-protocol population differed from that of the
intention-to-treat population by more than 10%,
the primary endpoint would have also been tested
on the per-protocol patient subset.
The original protocol was sized to test the non-
inferiority of 6-month versus 12-month DAPT on the
deﬁnite and/or probable ST rate and then amended to
modify the primary endpoint into a combined efﬁcacy
and safety primary endpoint. To validate the esti-
mated incidence of the primary endpoint, an inde-
pendent statistician conducted a safety interim
analysis when the ﬁrst 1,000 randomized patients
completed 12 months of follow-up. Results of the
interim analysis were evaluated by the data moni-
toring committee. The incidence of the primary end-
point at 12 months after randomization was 4.5%. At
the time of the blind interim analysis, the sample size
was therefore recalculated, taking the actual pro-
portion of the primary endpoint into account. Con-
sidering this low primary endpoint incidence and
keeping the absolute noninferiority margin of 2.0% of
the difference in the event proportions between the
6-month and the 12-month treatments, a power of
0.80 and a signiﬁcance level of 0.05 (1-tailed), 1,370
patients were estimated to be needed in each group.
Descriptive statistics (arithmetic mean, median as
indicated, minimum and maximum, and standard
deviation) were calculated for continuous variables.
Comparisons for continuous variables were per-
formed by means of unpaired Student t tests for
normal distributions or Mann-Whitney tests for non-
normal distributions. Absolute frequencies and per-
centages were obtained for qualitative variables.
Qualitative variables were compared by Pearson
chi-square tests for contingency tables with at least
5 expected cases per cell or by Fisher exact test for
contingency tables with fewer than 5 expected cases
per cell. For the main statistical analyses of primary
and secondary endpoints, 95% conﬁdence intervals
(CIs) are reported. Survival curves were computed by
the Kaplan-Meier method and compared using log-
rank tests. A Cox proportional hazard multivariable
regression analysis was also done. All variables with
TABLE 4 Medication Use During Trial in Patients Receiving
6 Months and 12 Months of DAPT
6-Month DAPT
(n ¼ 682)
12-Month DAPT
(n ¼ 717)
DAPT therapy at 6 months
Clopidogrel only 2 (0.3) 6 (0.9)
ASA only 3 (0.5) 5 (0.7)
ASA þ clopidogrel 618 (97.3) 655 (97.6)
ASA þ prasugrel 8 (1.3) 2 (0.3)
ASA þ ticagrelor 4 (0.6) 3 (0.4)
DAPT therapy at 12 months
Clopidogrel only 11 (1.8) 8 (1.2)
ASA only 392 (63.6) 13 (2.0)
ASA þ clopidogrel 208 (33.8) 622 (96.1)
ASA þ prasugrel 0 1 (0.2)
ASA þ ticagrelor 0 1 (0.2)
Drug therapy at 24 months
Aspirin 525 (96.5) 563 (97.9)
Values are n (%).
ASA ¼ acetylsalicylic acid; DAPT ¼ dual antiplatelet therapy.
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2091statistically signiﬁcant results from univariable anal-
ysis and those of clinical importance from previous
reports were included in the multivariable model.
A 1-sided p value <0.05 was considered statisti-
cally signiﬁcant. An independent statistician (B.M.C.)
performed all analyses using Statistical Analysis Sys-
tem version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
BASELINE CHARACTERISTICS. Because of enroll-
ment difﬁculties, only 1,399 patients were randomized
in the study and assigned to 6 (n ¼ 682) versus
12 (n ¼ 717) months of DAPT (Figure 1). Baseline
clinical and angiographic characteristics were well
balanced between the 2 study groups (Tables 1 and 2).
The mean age of the overall population was 65.2 
10.1 years; 31% of patients had diabetes mellitus,
5.5% had previous coronary artery bypass graft,
17.7% had previous PCI; 20.7% had a clinical history of
previous MI; and 61.6% had a clinical presentation of
stable angina.
Regarding baseline lesion and angiographic char-
acteristics, 299 patients had more than 1-vessel
disease (43.8%). Radial access was used in the ma-
jority of patients (n ¼ 967; 69.1%). According to the
American College of Cardiology/American Heart
Association classiﬁcation (11), 85% of patients had a
class B or C lesion. The left anterior descending cor-
onary artery was the target vessel for revasculariza-
tion in 825 patients (43.6%). Bifurcation lesions were
treated in 198 patients (14.2%). Among patients with
a second-generation DES implanted, 934 (41.2%)
received an Endeavor Resolute, 597 (26.3%) a Nobori,
250 (11%) a Promus, 207 (9.1%) a Xience, and 166
(7.3%) a Biomatrix stent. Procedural and hospital
outcomes are reported in Table 3.
Follow-ups at 12 and 24 months were successfully
performed in 1,260 (91%) and 1,136 (82.1%) patients,
respectively. Because of early study termination, the
average duration in the study was 643.17  212.13 and
640.21  202.18 days for the 6-month and 12-month
groups, respectively.
Medications used during the trial are reported in
Table 4. At the 12-month follow-up (primary
endpoint), DAPT use was 33.8% in the 6-month group
and 96.1% in the 12-month group. At 24 months,
96.5% of patients in the 6-month group and 97.9% in
the 12-month group were on aspirin monotherapy.
PRIMARY AND SECONDARY ENDPOINTS. There was
at least 1 occurrence of the primary composite
endpoint by 12 months in 31 patients in the 6-month
DAPT group (4.5%; 95% CI: 2.9 to 6.1) and 27 pa-
tients in the 12-month DAPT group (3.7%; 95% CI:2.3 to 5.1; p ¼ 0.469) (Table 5). There was a 0.8%
(95% CI: 2.4 to 1.7) difference in occurrence of the
primary endpoint between the 6-month and 12-
month groups. The upper limit of the 95% CI
was lower than the pre-set margin of 2%, conﬁrming
the noninferiority hypothesis (p < 0.05). The
Central Illustration shows estimates of the probability
of nonoccurrence of the primary endpoint in the
study groups at 12 months and between 6 and
12 months (panels A and B, respectively).
No statistically signiﬁcant difference in the sec-
ondary composite endpoints at 12 months and be-
tween 12 and 24 months was observed between the 2
study groups (5.3% vs. 4% difference, respectively:
1.2%, 95% CI: 1.0 to 3.4; p ¼ 0.273; and 1.5% vs. 2.2%,
difference: 0.7%, 95% CI: 2.1 to 0.6, p ¼ 0.289).
Figure 2 shows estimates of the probability of
nonoccurrence of the secondary endpoint in the
study groups.
Rates of occurrence of the individual components
of the primary endpoint are reported in Table 5. No
differences in MI were observed at 30 days (1.2%
vs. 1.4%; difference: 0.6%; 95% CI: 1.9 to 0.6;
p ¼ 0.328), between 1 and 6 months (0.9% vs. 0.4%;
difference: 0.4%; 95% CI: 0.3 to 1.3; p ¼ 0.280),
6 and 12 months (0.3% vs. 0.3%; difference: 0.0%;
95% CI: 0.5 to 0.6 p ¼ 0.960), and 12 and 24 months
(0.9% vs. 0.7%; difference: 0.1%; 95% CI: 0.7 to
1.0; p ¼ 0.681). Rates of urgent target vessel revas-
cularization (coronary artery bypass surgery or repeat
PCI) were also similar at the different time points (30
days, 0.2% vs. 0.1%, difference: 0.1%, 95% CI: 0.4 to
0.4, p ¼ 0.971; 6 months, 0.5% vs. 0.1%, difference:
TABLE 5 Clinical Outcomes in Patients Receiving 6 Months and
12 Months of DAPT*
Outcome
6-Month
DAPT
(n ¼ 682)
12-Month
DAPT
(n ¼ 717)
Difference
(95% CI) p Value
Primary endpoint
Primary efﬁcacy composite endpoint†
6–12 months 8 (1.2) 5 (0.7) 0.5% (1.5 to 0.7) 0.356
12 months 31 (4.5) 27 (3.7) 0.8% (2.4 to 1.7) 0.469
Secondary endpoints
Secondary efﬁcacy composite endpoint‡
12 months 36 (5.3) 29 (4) 1.2% (1.0 to 3.4) 0.273
12–24 months 10 (1.5) 16 (2.2) 0.7% (2.1 to 0.6) 0.289
Cardiac mortality
30 days 4 (0.6) 0 0.6% (0.0 to 1.2) 0.040
30 days–
6 months
1 (0.2) 2 (0.3) 0.1% (0.6 to 0.3) 0.592
6–12 months 0 1 (0.2) 0.1% (0.4 to 0.1) 0.329
12 months 5 (0.7) 3 (0.4) 0.3% (0.4 to 1.1) 0.435
12–24 months 1 (0.2) 3 (0.5) 0.3 (0.8 to 0.3) 0.341
24 months 6 (0.9) 6 (0.8) 0.0% (0.9 to 1.0) 0.931
MI
30 days 8 (1.2) 10 (1.4) 0.6% (1.9 to 0.6) 0.328
30 days–
6 months
6 (0.9) 3 (0.4) 0.4% (0.3 to 1.3) 0.280
6–12 months 2 (0.3) 2 (0.3) 0% (0.5 to 0.6) 0.960
12 months 16 (2.3) 15 (2.1) 0.2% (1.2 to 1.7) 0.747
12–24 months 5 (0.9) 4 (0.7) 0.2% (0.7 to 1) 0.681
24 months 21 (3.1) 19 (2.6) 0.4% (1.3 to 2.1) 0.630
Stroke
30 days 1 (0.2) 0 0.1% (0.1 to 0.4) 0.305
30 days–
6 months
2 (0.3) 2 (0.3) 0.0% (0.5 to 0.6) 0.960
6–12 months 3 (0.5) 0 0.4% (0.1 to 0.9) 0.075
12 months 6 (0.9) 2 (0.3) 0.6% (0.2 to 1.3) 0.136
12–24 months 0 1 (0.2) 0.1% (0.4 to 0.1) 0.329
24 months 6 (0.9) 3 (0.4) 0.5% (0.4 to 1.3) 0.280
Deﬁnite or probable stent thrombosis
30 days 2 (0.3) 1 (0.1) 0.1% (0.3 to 0.6) 0.534
30 days–
6 months
0 2 (0.3) 0.3 (0.7 to 0.1) 0.167
6–12 months 0 0 — —
12 months 2 (0.3) 3 (0.4) 0.1% (0.7 to 0.4) 0.694
12–24 months 1 (0.2) 0 0.1% (0.1 to 0.4) 0.305
24 months 3 (0.4) 3 (0.4) 0.0% (0.7 to 0.7) 0.951
Continued in the next column
TABLE 5 Continued
Outcome
6-Month
DAPT
(n ¼ 682)
12-Month
DAPT
(n ¼ 717)
Difference
(95% CI) p Value
Type 3 or 5 BARC bleeding
30 days 2 (0.3) 2 (0.3) 0.0% (0.5 to 0.5) 0.960
30 days–
6 months
1 (0.2) 4 (0.6) 0.4% (1.0 to 0.2) 0.197
6–12 months 1 (0.2) 2 (0.3) 0.1% (0.6 to 0.3) 0.592
12 months 4 (0.6) 8 (1.1) 0.5% (1.4 to 0.4) 0.283
12–24 months 1 (0.2) 0 0.1% (0.1 to 0.4) 0.305
24 months 5 (0.7) 8 (1.1) 0.4% (1.4 to 0.6) 0.455
Urgent TVR (PCI or CABG)
30 days 1 (0.2) 1 (0.1) 0.1% (0.4 to 0.4) 0.971
30 days–
6 months
3 (0.5) 1 (0.1) 0.3% (0.3 to 0.9) 0.292
6–12 months 0 1 (0.2) 0.1% (0.4 to 0.1) 0.329
12–24 months 0 1 (0.2) 0.1% (0.4 to 0.1) 0.329
Possible stent thrombosis
6 months 0 0 — —
24 months 0 0 — —
All bleeding
30 days 2 (0.3) 2 (0.3) 0.0% (0.6 to 0.6) 0.958
30 days–
6 months
2 (0.3) 4 (0.6) 0.2% (0.9 to 0.4) 0.450
6–12 months 1 (0.2) 2 (0.3) 0.1% (0.6 to 0.3) 0.593
12–24 months 1 (0.2) 2 (0.3) 0.1% (0.6 to 0.3) 0.593
All-cause
mortality
30 days 4 (0.6) 0 0.6% (0.0 to 1.1) 0.040
30 days–
6 months
4 (0.6) 6 (0.9) 0.1% (0.9 to 0.7) 0.795
6–12 months 0 2 (0.3) 0.1% (0.7 to 0.5) 0.695
12–24 months 6 (1.1) 7 (1.2) 0.4% (1.3 to 0.5) 0.409
Values are n (%). *Event rates based on Kaplan-Meier estimates. The p values were
calculated by log-rank test. The conﬁdence interval for differences in event rates
has not been calculated in cases of no clinical events in either group. †Deﬁned as a
clinical composite of cardiac death, MI, stroke, deﬁnite or probable stent throm-
bosis, or BARC type 3 or 5 bleeding at 12 months (adjudicated events). ‡Deﬁned as
a clinical composite of cardiac death; MI; stroke; deﬁnite or probable stent
thrombosis; or BARC type 2, 3, or 5 bleeding at 12 and 24 months (adjudicated
events).
BARC ¼ Bleeding Academic Research Consortium; CI ¼ conﬁdence interval;
TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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20920.3%, 95% CI: 0.3 to 0.9, p ¼ 0.292; 12 months, 0%
vs. 0.2%, difference: 0.1%, 95% CI: 0.4 to 0.1,
p ¼ 0.329; 24 months, 0% vs. 0.2%, difference: 0.1%,
95% CI: 0.4 to 0.1, p ¼ 0.329). Two ST cases occurred
in the 6-month group and 3 cases occurred in the 12-
month group within 12 months of follow-up (0.3%
[95% CI: 0.0 to 1.1] vs. 0.4% [95% CI: 0.1 to 1.2];
difference: 0.1%; 95% CI: 0.7 to 0.4; p ¼ 0.694); all
of these occurred within 6 months from the index
procedure, while the patients were on DAPT.
Conversely, 1 case occurred in the 6-month group
between 12 and 24 months of follow-up (0.2% vs. 0%;difference: 0.1%; 95% CI: 0.1 to 0.4; p ¼ 0.305): this
patient had stopped all antiplatelet medications. Of
note, no possible ST cases occurred during the clinical
follow-up period. Finally, no differences in stroke
incidence at 12 months and between 12 and 24 months
were observed between the 2 groups (respectively,
0.9% vs. 0.3%, difference: 0.6%, 95% CI: 0.2 to 1.3,
p ¼ 0.136; and 0% vs. 0.1%, difference: 0.1%, 95%
CI: 0.4 to 0.1, p ¼ 0.329).
Only 6 cases of any bleeding occurred in the
6-month group and 10 cases in the 12-month group.
No differences were noted at each speciﬁc time
period between the 2 groups (30 days, 0.3% vs. 0.3%,
difference: 0.0%, 95% CI: 0.6 to 0.6, p ¼ 0.958;
30 days to 6 months, 0.3% vs. 0.6%, difference:
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20930.2%, 95% CI: 0.9 to 0.4, p ¼ 0.450; 6 to 12 months,
0.2% vs. 0.3%, difference: 0.1%, 95% CI: 0.6 to 0.3,
p ¼ 0.593; and 12 to 24 months, 0.2% vs. 0.3%,
difference:0.1%, 95%CI:0.6 to 0.3, p¼0.593). BARC
3 or 5 bleeding occurred in 4 patients (0.6%) in the
6-month group and 8 patients in the 12-month
group (1.1%) at 12 months of follow-up (difference:
0.5%; 95 CI: 1.4% to 0.4%; p ¼ 0.283) and in 1 pa-
tient in the 6-month group between 12 and 24 months
of follow-up.
Finally, no signiﬁcant differences in all-cause and
cardiovascular mortality were observed at the dif-
ferent time points between the 6-month and
12-month DAPT regimens (Table 5).
PREDICTORS OF PRIMARY ENDPOINT AT MULTI-
VARIABLE ANALYSIS. By Cox regression multivari-
able analysis, predictors of the primary endpoint
were (Table 6): age $75 years (hazard ratio [HR]:
2.211; 95% CI: 1.234 to 3.962; p < 0.007), stent
type (Endeavor Resolute vs. Biomatrix/Xience/Pro-
mus, HR: 2.336; CI: 1.051 to 5.190; p ¼ 0.019), mean
number of stents (for each unit increase; HR: 1.410;
95% CI: 1.128 to 1.741; p ¼ 0.002), mean stent
length (for each 5-U increase, HR: 1.383; 95%
CI: 1.135 to 1.685; p ¼ 0.001), and mean stent size
(for each 2.5-U increase; HR: 1.326; 95% CI: 1.106
to 1.590; p ¼ 0.002). Finally, DAPT 6 versus 12 months
was not a signiﬁcant independent predictor of the
primary endpoint (HR: 1.272; 95% CI: 0.754 to 2.145;
p ¼ 0.367).Colombo, A. et al. J Am Coll Cardiol. 2014; 64(20):2086–97.
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CENTRAL ILLUSTRATION Kaplan-Meier Estimates of the Probability of
Nonoccurrence of the Primary Endpoint
There is no difference in the occurrence of the primary endpoint at 12 months (upper
panel) and between 6 and 12 months (lower panel) for patients assigned to 6-month
versus patients assigned to 12-month DAPT. Blue line ¼ 6-month DAPT group;
salmon line ¼ 12-month DAPT group. DAPT ¼ dual antiplatelet therapy.DISCUSSION
The main results of the SECURITY trial are as follows:
1. In our study population undergoing PCI with
second-generation DES, 6 months of DAPT
appeared noninferior to a 12-month regimen with
respect to the primary composite endpoint of car-
diac death, MI, stroke, deﬁnite or probable ST, or
BARC type 3 or 5 bleeding at 12 months of clinical
follow-up.
2. Multivariable analysis found age $75 years, stent
type used, mean number of stents implanted,
mean stent length, and mean stent size as signiﬁ-
cant independent predictors of the primary
endpoint. Of note, following multivariable adjust-
ment, results for 6 versus 12 months of DAPT were
not signiﬁcant.
3. With respect to incidence of the secondary
composite endpoints deﬁned by the study pro-
tocol, 6 months DAPT appeared noninferior to 12
months.Introduction of DES in clinical practice drastically
changed the efﬁcacy of PCI by reducing the need for
repeated target lesion and target vessel revasculariza-
tion (12,13). However, several retrospective analyses
from real-world registries and clinical trials reported a
higher incidence of late and very late ST with ﬁrst-
generation DES use compared with bare-metal stents
(14–16). The pathological basis of late clinical events
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FIGURE 2 Kaplan-Meier Estimates of the Probability of Nonoccurrence of the
Secondary Endpoint
Nonoccurrence of the secondary endpoint in the 6-month and 12-month DAPT groups is
shown. There is no difference in freedom from occurrence of the primary and secondary
endpoints for patients assigned to 6-month versus patients assigned to 12-month DAPT.
Blue line ¼ 6-month DAPT group; salmon line ¼ 12-month DAPT group. DAPT ¼ dual
antiplatelet therapy.
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2094with DES seems related mainly to delayed vascular
healing and local stent strut hypersensitivity (17).
Concerns regarding ST focused the scientiﬁc com-
munity’s attention on the optimal DAPT duration
following DES implantation. Several studies initially
suggested potential beneﬁts of long-term DAPT to
prevent late thrombotic events (18). Moreover, several
observational studies found a signiﬁcant association
between early DAPT discontinuation and occurrence
of thrombotic complications following DES implanta-
tion (14,19–22). Current guideline recommendations
for DAPT following PCI arose from these initial obser-
vations. The American College of Cardiology/American
Heart Association and European Society of Cardio-
logy guidelines recommend, in patients who havePredictors of the Primary Endpoint at Multivariable Analysis
Variables in the Model* HR 95% CI p Value
rs 2.211 1.234–3.962 0.007
Resolute vs. Biomatrix/Xience/Promus 2.336 1.051–5.190 0.019
ber of stents (for each unit increase) 1.410 1.128–1.741 0.002
t length (for each 5-U increase) 1.383 1.135–1.685 0.001
t size (for each 2.5-U increase) 1.326 1.106–1.590 0.002
ellitus 0.069
vs. none 0.895 0.464–1.729
s. none 2.349 1.080–5.106
s. 12-month 1.272 0.754–2.145 0.367
1.596 0.897–2.838 0.111
ﬁtted on 1,360 patients with 57 primary events because of missing values.
ard ratio; other abbreviations as in Tables 1 and 5.undergone DES-PCI, a DAPT duration of 12 months or
6 to 12 months in patients not at high risk for
acute coronary syndrome and not at high risk of
bleeding, respectively (1,2). Although these initial ob-
servations were done in the ﬁrst-generation DES era,
guideline recommendations for DAPT were extended to
newer-generation DES, notwithstanding the lack of
supporting evidence from RCTs.
Before our study, several randomized trials
demonstrated the safety and efﬁcacy of reduced-
term versus prolonged-term DAPT. The REAL-LATE
(Correlation of Clopidogrel Therapy Discontinuation
in Real-World Patients Treated With Drug-Eluting
Stent Implantation and Late Coronary Arterial
Thrombotic Events) and the ZEST-LATE (Evaluation
of the Long-Term Safety After Zotarolimus-Eluting
Stent, Sirolimus-Eluting Stent, or Paclitaxel-Eluting
Stent Implantation for Coronary Lesions–Late Coro-
nary Arterial Thrombotic Events) trials demon-
strated no signiﬁcant beneﬁt in preventing major
adverse cardiovascular events with clopidogrel con-
tinuation compared with clopidogrel discontinuation
after 12 months in patients with DES implantation.
Similarly, the DES-LATE (Optimal Duration of Dual
Antiplatelet Therapy After Drug-Eluting Stent
Implantation) trial explored the use of DAPT for an
additional 24 months in patients who were on
12-month DAPT without complications. Again,
prolonged DAPT did not reduce major adverse car-
diovascular events compared with aspirin alone
(23). Moreover, the EXCELLENT trial reported
the noninferiority of 6 months versus 12 months
of DAPT in preventing major adverse cardio-
vascular events following everolimus-eluting or
sirolimus-eluting stent implantation. However, the
EXCELLENT study was designed to demonstrate the
noninferiority of target vessel failure (cardiac death,
MI, or ischemia-driven revascularization), the non-
inferiority margin was wide, and the study was
underpowered for death or MI as the primary
endpoint. Additionally, the PRODIGY trial demon-
strated the noninferiority of 6 months of DAPT
compared with 24 months, in terms of death, ST,
MI, or cerebrovascular accident in patients who
received a balanced mixture of DES or bare-metal
stents.
Several reports suggested the association of
second-generation DES with reduced rates of very
late ST, compared with ﬁrst-generation DES (24–26).
However, the optimal DAPT duration following
second-generation DES implantation is still debated.
A pre-speciﬁed subanalysis from the PRODIGY trial
reported reduced ST rates with paclitaxel-eluting
stents and a prolonged (24-month) DAPT regimen
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2095(27). Conversely, no differences in ST between
24-month and 6-month DAPT were observed with the
other stent types. In addition, the RESET trial (REal
Safety and Efﬁcacy of 3-month dual antiplatelet
Therapy following zotarolimus-eluting stent implan-
tation) demonstrated noninferiority for the primary
composite endpoint (cardiac death, MI, ST, target
vessel revascularization, or bleeding) at 1 year with
3 months of DAPT following Endeavor zotarolimus-
eluting stent implantation compared with 12 months
of DAPT after other DES use (4). A substudy from the
PROTECT (Patient Related OuTcomes with Endeavor
vs. Cypher stenting Trial) study found a strong
interaction among stent type used, DAPT duration,
and ST events. Speciﬁcally, very late ST events
(>1 year) with sirolimus-eluting stents were related
to DAPT discontinuation, whereas no differences in
very late ST events with Endeavor zotarolimus-
eluting stents were observed in the presence of
DAPT (28). Finally, the OPTIMIZE noninferiority trial,
comparing 3 versus 12 months of DAPT in 3,119 pa-
tients with stable coronary artery disease undergoing
PCI with zotarolimus-eluting stents, ﬁrst demon-
strated the noninferiority of 3 months versus 12
months of DAPT using 1 speciﬁc type of second-
generation DES.
Our study, suggesting the noninferiority of
6 months versus 12 months of DAPT following im-
plantation of different types of second-generation
DES in the primary study endpoint, contributes to
the evidence that reduced DAPT is safe and effective
with currently used DES in patients with the charac-
teristics of our study population.
One of the most evident results of our study,
compared with previous studies, is the low rate of
adverse cardiovascular events at clinical follow-up.
This is consistent with improvements related to
the introduction of second-generation DES in clinical
practice and the low-risk clinical and lesion proﬁles
of the patients in our study (Tables 1 and 2). Conse-
quently, at 1-year clinical follow-up, the overall pri-
mary composite endpoint and deﬁnite or possible
ST rates were 4.5% and 3.7%, respectively, in the
6-month versus the 12-month group. Deﬁnite or
possible ST rates observed in our study compared
favorably with reported rates in the OPTIMIZE trial
(using zotarolimus-eluting stents) of 0.8% at 1 year
in both the 3-month and 12-month DAPT groups. Our
study also compared favorably in this respect to the
PRODIGY and EXCELLENT trials, which reported ST
incidences of 1.5% and 0.9%, respectively, in the
6-month DAPT group. However, almost 74% of
patients in the PRODIGY trial and 50% of patients in
the EXCELLENT trial presented with an acutecoronary syndrome. Conversely, our results are very
similar to those of the RESET trial, which reported a
1-year ST incidence of 0.2% using the Endeavor
zotarolimus-eluting stent plus 3 months of DAPT,
and 0.3% using sirolimus-eluting, everolimus-
eluting, or Resolute zotarolimus-eluting stent plus
12 months of DAPT. Similar to our study, the ma-
jority of RESET trial patients (85%) presented with
stable or unstable angina.
Following multivariable adjustment, DAPT dura-
tion did not independently predict the primary
endpoint in our study, further demonstrating the
safety of a 6-month regimen. By contrast, factors
reﬂecting the burden of coronary artery stenting
(mean stent length, size, and number of stents
implanted) were strong independent primary end-
point predictors, even with second-generation DES.
Independent of DAPT duration, patients in whom
multiple smaller or longer stents are implanted may
beneﬁt from high-potency P2Y inhibitors. Finally, as
expected, age $75 years was another independent
predictor of mortality. Because of the low event
rates and the implantation of an Endeavor Resolute
DES in >40% of patients, we cannot draw conclusions
regarding the correlation between primary endpoint
occurrence and a speciﬁc stent type. The association
of increased events with Resolute stent implantation
should be interpreted cautiously, as the low event
number, combined with the high Resolute implanta-
tion rate, increases the probability that this is due
to chance.
Of note, our study did not ﬁnd any difference in
bleeding events between reduced and prolonged
DAPT. The PRODIGY trial reported a signiﬁcantly
higher risk of hemorrhagic complications in patients
allocated to the 24-month DAPT cohort. Most prob-
ably, our study population’s low risk proﬁle and the
12-month DAPT duration were both insufﬁcient to
increase the hazard of bleeding events.
STUDY LIMITATIONS. Our study has several impor-
tant limitations to consider:
1. Considering the low event rates observed during
the trial, our study was underpowered to demon-
strate any difference in single outcomes such
as cardiac death, MI, ST, bleeding, or stroke. Stu-
dies speciﬁcally designed to demonstrate differ-
ences in single outcomes are currently ongoing
(NCT00977938 and NCT00661206).
2. Our study population included patients with
reasonably low-risk clinical proﬁles; therefore,
generalization of our results to patients at moder-
ate or high risk cannot be made. Moreover, the
lesion risk proﬁle of our study population had
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
duration of DAPT following deployment of DES in
patients not considered at high risk of stent thrombosis
varies from 6 to >12 months according to American
College of Cardiology/American Heart Association
and European Society of Cardiology guidelines.
COMPETENCY IN PATIENT CARE: The results of
the SECURITY trial support withdrawal of DAPT after
6 months in low-risk patients undergoing deployment
of second-generation DES.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to deﬁne the optimum duration of DAPT
in patients at higher risk of stent thrombosis.
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2096low prevalence of bifurcation lesions and complex
lesions. Our conclusions are therefore applicable
to a subset of patients at low risk and relatively
simple coronary anatomy.
3. The primary endpoint rate was lower than ex-
pected at the interim analysis (4.5% vs. 6%).
Therefore, keeping all the other assumptions of
the study design unchanged, the sample size was
reduced from 3,600 (originally expected) to 2,800.
The actual number of 1,399 included patients
allowed declaration of noninferiority, given the
superimposable occurrence of the primary end-
point in the 2 groups. Because of the reduced
number of enrolled patients, compared with the
original sample size, and the small difference in
primary endpoint occurrence between the 2 study
groups, the power is lower than originally planned
(around 60% following recalculation). Neverthe-
less, the upper limit of the CI is lower than the
preset margin of 2%, conﬁrming the noninferiority
hypothesis.
4. As a practical approach, we randomized patients at
the time of the index procedure, rather that at 6
months, which should be considered a debatable
limitation.
5. Almost 34% of patients in the 6-month group
continued DAPT after 6 months. As this could
have affected our results, the per-protocol analysis
excluding these patients (948 excluded patients
with 32 primary events) conﬁrmed the results of
the intention-to-treat analysis.
6. Although stent type appeared to be a predictor
of the primary endpoint, because several types
were allowed by the study protocol, and because
the majority of patients were treated with the
Endeavor Resolute DES, we cannot determine the
real association between the stent type used and
occurrence of the primary endpoint.
7. We cannot exclude that the low incidence of major
adverse cardiovascular events in our trial couldhave been due to under-reporting of adverse
events by the participating centers, notwith-
standing the continuous monitoring of the sites by
an independent clinical research organization.
However, source data veriﬁcation was performed
in 40% of patients.
CONCLUSIONS
In a low-risk population, as in this study, the non-
inferiority hypothesis for 6 versus 12 months of
DAPT following second-generation DES implantation
appears accepted regarding the incidence of cardiac
death, MI, stroke, deﬁnite or probable ST, or BARC
type 3 or 5 bleeding at 12 months.
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